Bayesian Nonparametric Sensitivity Analysis of Multiple Comparisons Under Dependence

George Karabatsos¹

¹Departments of Mathematics, Statistics, and Computer Sciences and Educational Psychology in Statistics and Measurement University of Illinois-Chicago e-mail: gkarabatsos1@gmail.com, georgek@uic.edu

October 11, 2024

Abstract

This short communication introduces a sensitivity analysis method for Multiple Testing Procedures (MTPs), based on marginal p-values and the Dirichlet process prior distribution. The method measures each p-value's insensitivity towards a significance decision, with respect to the entire space of MTPs controlling either the family-wise error rate (FWER) or the false discovery rate (FDR) under arbitrary dependence between p-values, supported by this nonparametric prior. The sensitivity analysis method is illustrated through 1,081 hypothesis tests of the effects of the COVID-19 pandemic on educational processes for 15-year-old students, performed on a 2022 public dataset. Software code for the method is provided.

Keywords: Sensitivity analysis; Multiple testing; False discovery rate; Familywise error rate; Dirichlet process.

1 Introduction

P-values are ubiquitous in science and provide a common language for the communication of statistics. Most statistical analyses routinely output dependent (correlated) *p*-values from hypothesis tests, which makes important using MTPs that are valid under arbitrary dependence between p -values. MTPs based on marginal p-values remain very popular in practice [\(Tamhane & Gou, 2018\)](#page-7-0), despite concerns about them (e.g., [Wasserstein & Lazar, 2016\)](#page-8-0). This is because marginal p-values are easy to apply, readily available from any statistical software, and can reduce the results of different (e.g., t, Wilcoxon, χ^2 , and/or log-rank) test statistics to a common interpretable p -value scale, without requiring assumptions or explicit modeling of the potentially-complex joint distributions of the test statistics, having typically-unknown correlations.

For example, due to the widespread popularity of MTPs based on marginal *p*-values [\(Tamhane & Gou,](#page-7-1) [2022\)](#page-7-1), the Food and Drug Administration (FDA) now provides extensive discussions of them in their Multiplicity Guidance Document on analyzing data from clinical trials [\(U.S. Department of Health and Human](#page-8-1) [Services, Food and Drug Administration, 2022,](#page-8-1) §4, Appendix). This references another FDA document [\(U.S. Department of Health and Human Services, Food and Drug Administration, 2021\)](#page-8-2) that provides lengthy discussions on the important scientific and public role of performing sensitivity analysis of statistical results, with respect to deviations from underlying statistical assumptions, in order to examine and enhance the robustness, precision, and understanding of statistical conclusions (e.g., of treatment effects). Since any *p*-value is a deterministic transformation of a test statistic (e.g., measuring the treatment effect) in a standardized way on the [0,1] interval [\(Dickhaus, 2014,](#page-6-0) p.17), it is reasonable to apply sensitivity analysis to p-values (e.g., [Rosenbaum, 2002,](#page-7-2) Ch.4) by integrating the results of the sensitivity analysis over explicit prior distributions for parameters that potentially drive the sensitivities of the results [\(Greenland, 2005\)](#page-7-3).

This short communication introduces a sensitivity analysis method for MTPs valid under arbitrary dependence between the p-values, and based on the Bayesian nonparametric (BNP), Dirichlet process (DP) prior distribution assigned on the entire space of distributions [\(Ferguson, 1973\)](#page-6-1).

2 Review of MTPs Valid Under Arbitrary Dependence

We formally review the MTP framework (from [Blanchard & Roquain, 2008;](#page-6-2) [Dickhaus, 2014;](#page-6-0) [Fithian & Lei,](#page-6-3) [2022;](#page-6-3) [Tamhane & Gou, 2022\)](#page-7-1) underlying the BNP sensitivity analysis method, described later in §3.

Let (X, \mathfrak{X}, P) be a probability space, with P belonging to a set or "model" P of distributions, which can be parametric or non-parametric model. A null hypothesis is a subset (submodel) $H \subset \mathcal{P}$ of distributions on $(\mathcal{X}, \mathfrak{X})$, while $P \in H$ means that P satisfies H. In multiple testing, one is interested in determining whether P satisfies distinct null hypotheses, belonging to a certain countable or continuous set (family) H of candidate null hypotheses. Also, let Λ be any fixed finite positive volume measure on H , denoted by $\Lambda(S) = |S|$ for any $S \subset \mathcal{H}$. Let $\mathcal{H}_0(P) = \{H \in \mathcal{H} \mid P \in H\} \subseteq \mathcal{H}$ be the set of *true null hypotheses*, and let $\mathcal{H}_1(P) = \mathcal{H} \backslash \mathcal{H}_0(P)$ be the set of *(truly) false null hypotheses*, under any $P \in \mathcal{P}$. Throughout, we assume (unless indicated otherwise) that H is at most countable, with counting measure $\Lambda(\cdot) = |\cdot|$. In the most common MTP settings, H is a finite set of m null hypotheses, $\mathcal{H} = \{H_1, \ldots, H_m\}$, and $\Lambda(\cdot) = |\cdot| = \text{Card}(\cdot)$ is the cardinality measure, with $m \in \mathbb{Z}^+$ the number of candidate null hypotheses, $m_0(P) = |\mathcal{H}_0(P)|$ the number of true nulls, $m_1(P) = |\mathcal{H}_1(P)|$ the number of truly false nulls, and $\pi_0(P) = m_0(P)/m$ the proportion of true nulls, for any true data-generating distribution, $P \in \mathcal{P}$.

A *multiple testing procedure (MTP)* is a decision function, $\mathcal{R}: x \in \mathcal{X} \mapsto \mathcal{R}(x) \subset \mathcal{H}$, designating the subset of rejected null hypotheses, such that the indicator function $1\{H \in \mathcal{R}(x)\}\$ is measurable for any $H \in \mathcal{H}$, and for any dataset $x \sim P$ randomly sampled under any given true (population) distribution $P \in \mathcal{P}$, which is typically unknown in statistical analyses of real data. A Type I error (Type II error, respectively) occurs when a true null hypothesis H is wrongly rejected, $H \in \mathcal{R}(x) \cap \mathcal{H}_0(P)$ (a false null hypothesis H is wrongly not rejected, $H \notin \mathcal{R}(x) \cap \mathcal{H}_1(P)$, resp.), for any dataset $x \sim P$ sampled under any given distribution $P \in H \subset \mathcal{P}$ ($P \in \mathcal{P} \setminus H$, resp.).

A typical MTP R is a function $\mathcal{R}(\mathbf{p})$ of a family of p-values, $\mathbf{p} = (p_H, H \in \mathcal{H})$. We assume that for each null hypothesis $H \in \mathcal{H}$ there exists a (measurable) p-value function $p_H : \mathcal{X} \to [0,1]$ such that if H is true, then the distribution of $p_H(X)$ is marginally super-uniform (i.e., stochastically not smaller than a Uniform(0,1) random variate):

$$
\mathbb{P}_{X \sim P}[p_H(X) \le t] \le t, \text{ for } \forall P \in \mathcal{P}, \ \forall H \in \mathcal{H}_0(P), \text{ and } \forall t \in [0,1],
$$

while for countable hypotheses H, the p-value from a test of any null hypothesis $H_i \in \mathcal{H}$ is denoted p_i $(= p_{H_i})$. A p-value $p_H(x)$ is *calibrated* if it has a Uniform(0,1) distribution over random datasets $x \sim P \in$ $H \subset \mathcal{P}$ under the null. Any Neyman-Pearson type test of a simple (e.g., point-null) hypothesis gives rise to a calibrated p-value if its underlying test statistic has a stochastically smaller continuous distribution under the null, compared to that under the alternative hypothesis [\(Dickhaus, 2014,](#page-6-0) Theorem 2.2). If necessary, one of many techniques can be used to better-calibrate the p-value, including for a test of a discrete model, composite null hypothesis, or model checking [\(Dickhaus et al., 2012;](#page-6-4) [Dickhaus, 2013;](#page-6-5) [Gosselin, 2011;](#page-7-4) [Moran et al., 2024,](#page-7-5) references therein).

When testing multiple null hypotheses H , one traditional criterion for Type I error control is the FWER, the probability of rejecting one or more true null hypotheses [\(Hochberg & Tamhane, 1987\)](#page-7-6):

FWER($\mathcal{R}; P$) = Pr{Reject at least one true null hypothesis H from $\mathcal{H}_0(P) \subseteq \mathcal{H} : P \in \mathcal{P}$ }. (1)

Another traditional criterion is the FDR [\(Benjamini & Hochberg, 1995\)](#page-6-6), the expected False Discovery Proportion (FDP):

$$
\text{FDR}(\mathcal{R}; P) := \mathbb{E}_{X \sim P} \left[\text{FDP}(\mathcal{R}(X); P) \right] = \mathbb{E}_{X \sim P} \left[\frac{|\mathcal{R}(X) \cap \mathcal{H}_0(P)|}{\max\{|\mathcal{R}(X)|, 1\}} \right].
$$
 (2)

The main goal in multiple hypothesis testing is to maximize the expected number of rejections while controlling the FWER or FDR at a preset small level $\alpha \in (0,1)$, typically $\alpha = 0.05$ or 0.01, etc. Any MTP is said to *strongly control the FWER* (*FDR*, resp.) if $\text{FWER}(\mathcal{R}; P) \leq \alpha$ (if $\text{FDR}(\mathcal{R}; P) \leq \pi_0 \alpha \leq \alpha$, resp.) for any chosen level $\alpha \in (0,1)$ and for all $P \in \mathcal{P}$ (and all $\pi_0 \in [0,1]$, resp.) [\(Hochberg & Tamhane, 1987;](#page-7-6) [Benjamini & Hochberg, 1995\)](#page-6-6). Therefore, under FWER (FDR, resp.) control, any null hypothesis $H_i \in \mathcal{H}$ is rejected if its p-value $p_i < \alpha$ (if $p_i < \pi_0 \alpha < \alpha$, resp.). Also, FDR \leq FWER, with FDR $=$ FWER if all null hypotheses are true, and therefore $FWER \leq \alpha$ implies $FDR \leq \alpha$, meaning that FDR control is less strict than FWER control, and that a *p*-value declared significant under FWER control is a stronger result than under FDR control. FWER control is typically used in confirmatory studies (e.g., Phase 3 clinical trials) which usually tests a small number (e.g., \leq 20) of null hypotheses, whereas FDR control is generally used in exploratory (e.g., genomic or microarray) studies involving testing a very large number of null hypotheses (e.g., $m \ge 1000$). FWER control is too stringent and unnecessary for exploratory studies, which only aim to highlight interesting findings [\(Tamhane & Gou, 2022\)](#page-7-1).

Let $p_{(1)} \leq \cdots \leq p_{(m)}$ be the order statistics of m p-values, with corresponding ordered null hypotheses $H_{(1)},\ldots,H_{(m)}$. A *step-up MTP* $\mathcal{R}_{SU}^{\Delta_{\alpha}}$ specifies a non-decreasing sequence of thresholds, $0 \leq \Delta_{\alpha}(H_{(1)}) \leq$ $\cdots \leq \Delta_{\alpha}(H_{(m)}) \leq 1$, and then rejects the null hypotheses having the $R_{\alpha}(x)$ smallest p-values, with:

$$
R_{\alpha}(x) = \max_{r \in \{1, \dots, m\}} \{r : p_{(r)}(x) \le \Delta_{\alpha}(H_{(r)})\}.
$$
 (3)

A *step-down MTP* $\mathcal{R}_{SD}^{\Delta_{\alpha}}$, for step(s) $i=1,2,\ldots\leq m$, rejects $H_{(i)}$ if $p_{(i)}\leq\Delta_{\alpha}(H_{(i)})$ and then continues to test $H_{(i+1)}$; and otherwise, stops testing without rejecting the remaining hypotheses $H_{(i)}, \ldots, H_{(m)}$.

The widely used [Benjamini & Hochberg](#page-6-6) (BH; [1995\)](#page-6-6) step-up MTP takes $\Delta_{\alpha}(H_{(r)}) = \alpha \beta(r) = \alpha r/m$ with shape function $\beta(r) = r$, and was proven to strongly control FDR $\leq \pi_0 \alpha \leq \alpha$ under independent p-values. The default BH MTP assumes $\pi_0 \equiv 1$, while the adaptive BH MTP is based on any of the available estimators of π_0 (e.g., [Benjamini et al., 2006;](#page-6-7) [Murray & Blume, 2021;](#page-7-7) [Neumann et al., 2021;](#page-7-8) [Biswas et al.,](#page-6-8) [2022,](#page-6-8) and references therein). Simulation studies [\(Farcomeni, 2006;](#page-6-9) [Kim & van de Wiel, 2008\)](#page-7-9) showed that such a BH MTP is robust to the types of dependencies among p-values that often occur in practice, while being conservative, without theoretical guarantees of FDR control, and it is challenging to reliably estimate π_0 from arbitrarily-dependent p-values (e.g., [Blanchard & Roquain, 2009;](#page-6-10) [Fithian & Lei, 2022\)](#page-6-3).

It was proven that if ν is any arbitrary probability measure on $(0, \infty)$, then the step-up procedure with shape function $\beta_{\nu}(r) = \int_0^r x \, d\nu(x)$, which corresponds to the threshold function $\Delta_{\alpha,\nu}(H_{(r)}) = \alpha \beta_{\nu}(r)/m$ for countable hypotheses H, or to the general threshold function $\Delta_{\alpha,\nu}(H_{(r)})=\alpha\pi(H)\beta_\nu(r)$ for countable or continuous hypotheses H, strongly controls FDR $\leq \alpha \pi_0 \leq \alpha$ under arbitrary dependence between the p-values, where $\pi : \mathcal{H} \to [0,1]$ is a probability density with respect to Λ , and $\pi_0 = \sum_{H \in \mathcal{H}_0} \Lambda(\{H\}) \pi(H)$ (or $\pi_0 = \int_{H \in \mathcal{H}_0} \Lambda(\{H\}) \pi(H) dH = 1$) [\(Blanchard & Roquain, 2008,](#page-6-2) [2018\)](#page-6-11). The possibility of using different weights $\pi(H)$ (or $\Lambda({H})$, resp.) over countable H gives rise to *weighted p-values* (*weighted FDR* [\(Benjamini & Hochberg, 1997\)](#page-6-12), resp.).

Specifically, for any finite set of unweighted m null hypotheses H and p-values, the [Benjamini & Yeku](#page-6-13)[tieli](#page-6-13) (BY; [2001\)](#page-6-13) distribution-free linear step-up MTP assumes probability measure $\nu({k}) = (k \sum_{j=1}^{m} \frac{1}{j})$ $(\frac{1}{j})^{-1}$ with support in $\{1,\ldots,m\}$, with corresponding threshold function $\Delta_{\alpha,\nu}(H_{(r)},r) = \alpha\beta_{\nu}(r)/m$ based on linear shape function $\beta_{\nu}(r) = \sum_{k=1}^{r} k\nu(\lbrace k \rbrace) = r/(\sum_{j=1}^{m} \frac{1}{j})$ $\frac{1}{j}$). While the BY MTP controls FDR for arbi-trary dependencies between p-values, it is highly conservative (e.g., [Farcomeni, 2006\)](#page-6-9). Other choices of ν can sometimes improve on the BY procedure's power, depending on the nature of the dependencies among the given m p-values. This includes a truncated exponential distribution ν defined in [0, m] with a free scale parameter, which provides a wide range of shape functions, while being more flexible than the BY MTP [\(Blanchard & Roquain, 2008,](#page-6-2) p.978).

MTPs that strongly control FWER under arbitrary dependencies between p-values include the [Bonfer](#page-6-14)[roni](#page-6-14) [\(1936\)](#page-6-14) MTP, defined by threshold function $\Delta_\alpha(H_{(r)}) = \alpha\beta(r)/m = \alpha/m$; the slightly more powerful [Holm](#page-7-10) [\(1979\)](#page-7-10) step-down MTP, defined by $\Delta_{\alpha}(H_{(r)}) = \alpha \beta(r)/m = \alpha/(m-r+1)$ [\(Blanchard & Roquain,](#page-6-2) [2008,](#page-6-2) p.977); and the weighted Bonferroni MTP, defined by $\Delta_{\alpha}(H_{(r)}) = \alpha \pi(H_{(r)}) \beta(r) = \alpha w_{(r)}$, with weight $w_i \in [0, 1]$ assigned to each $H_i \in \mathcal{H}$ where $\sum_{i=1}^{m} w_i = 1$.

3 MTP Sensitivity Analysis Method

For any probability space $(\mathcal{X}, \mathcal{A}, G)$, a random probability measure ν is said to follow a Dirichlet process prior with baseline probability measure ν_0 and mass parameter M, denoted $\nu \sim DP(M\nu_0)$, if

$$
(\nu(B_1), \dots, \nu(B_m)) \sim \text{Dirichlet}_m(M\nu_0(B_1), \dots, M\nu_0(B_m))
$$
\n⁽⁴⁾

for any partition B_1, \ldots, B_m of the sample space X [\(Ferguson, 1973\)](#page-6-1).

For each of a given set of m ordered p-values, $\{p_{(r)}\}_{r=1}^m$, the MTP sensitivity analysis method counts the proportion of times the p-value is declared significant, over the DP prior predictive distribution:

$$
Pr[\mathbf{1}(r \le R_{\alpha,\nu}(x); p_{(r)}) = 1, r = 1, ..., m]
$$
\n(5a)

$$
= \int \cdots \int [\mathbf{1}(r \leq R_{\alpha,\nu}(x); p_{(r)}) = 1, r = 1, \ldots, m] \mathcal{D}_m(\mathrm{d}\nu_1, \ldots, \mathrm{d}\nu_m \mid M\nu_0), \tag{5b}
$$

where

$$
R_{\alpha,\nu}(x) = \max_{r \in \{1,\dots,m\}} \{r : p_{(r)}(x) \le \Delta_{\alpha,\nu}(H_{(r)})\}
$$
(6a)

$$
= \max_{r \in \{1, \dots, m\}} \left\{ r : p_{(r)}(x) \le \frac{\alpha}{m} \sum_{j=1}^{r} j \nu(j-1, j) \right\},\tag{6b}
$$

and $\mathcal{D}_m(\nu_1,\ldots,\nu_m \mid M\nu_0)$ (with $\nu_r \equiv B_i = \nu(r-1,r]$ for $r = 1,\ldots,m$) denotes the cumulative distribution function of the Dirichlet_m $(M\nu_0(B_1), \ldots, M\nu_0(B_m))$ distribution. By default, we set M to a small value with $\nu_0(r-1,r] \equiv (r \sum_{j=1}^m \frac{1}{j})$ $\frac{1}{j}$)⁻¹, which matches (in prior expectation) the probability measure ν defining the BY MTP.

The MTP sensitivity analysis method, based on the DP prior predictive [\(5\)](#page-3-0), provides for each $p_{(r)}$ -value an index ranging between 0 and 1, measuring this p -value's level of insensitivity towards a significance decision (for $r = 1, \ldots, m$). A value of 1 indicates maximal insensitivity, and with respect to the entire space of MTPs that are valid under arbitrary dependence between the p -values. The level of support of this entire space depends on the degree of smallness of M, as illustrated later.

Monte Carlo estimation of the prior predictive [\(5\)](#page-3-0) can be achieved using R code [\(R Core Team, 2024\)](#page-7-11):

```
# p: is the (input) vector of observed p-values.
set.seed(123) # For reproducibility.
p = runif(11, min = 0, max = 0.03) # Example p-values (random)
m = length(p)alpha = 0.05p.sort = sort(p)p.sortI = sort.int(p, index.return = TRUE)$ix
# Draw DP random samples of nu and corresponding thresholds (Deltas):
N = 1000 # Number of Monte Carlo samples
M = 10**(-3) # Prior mass of the Dirichlet process (DP)
nu0 = M * (matrix(rep(1:m, N), m, N)*sum(1/(1:m))**-1)rnd.nu = matrix(rgamma(m*N, shape = nu0, rate = 1), m, N)
rnd.nu = rnd.nu / matrix(colSums(rnd.nu), nrow = 1)[rep(1,m),]
r = \text{matrix}(\text{rep}(1:m, N), m, N)rnd.beta= apply(r * rnd.nu, 2, cumsum)
rnd.Delta= t(alpha * rnd.beta / m)
P.sort = matrix(p.sort, nrow = 1) [rep(1,N),]rnd.R = matrix(max.col(P.sort \le rnd.Delta, "last"), ncol=1) [, rep(1, m)]
PrSig.p = colMeans(matrix(1:m,nrow=1)[rep(1,N),] \le rnd.R, na.rm = T)
PrSig.p # Shows insensitivity of each p-value towards significance.
```
The DP MTP sensitivity analysis method emphasizes prior predictive inference as in [Box](#page-6-15) [\(1980\)](#page-6-15), while adopting the view that for statistical analysis, the two Bayesian ingredients of likelihood and prior should be kept separate (instead of combined into a posterior distribution), while making the full background information of these ingredients explicitly available [\(Fraser, 2011;](#page-6-16) [Fraser & Reid, 2016,](#page-6-17) p.314; p.7; resp.).

The BNP sensitivity analysis method also can easily be extended to either (un)weighted countable or continuous hypotheses H, to (un)weighted p-values, and/or to online FDR after modifying the level α of the m tests to change over time, $\alpha_1, \ldots, \alpha_m$, based on the number of discoveries made so far, or on the time of the most recent discovery [\(Javanmard & Montanari, 2015,](#page-7-12) [2018\)](#page-7-13).

4 Illustration

For greater ease of exposition and without any loss of generality, this sensitivity analysis method is illustrated for finite H and unweighted MTP settings. We analyze a subset of the data from the Programme for International Student Assessment (PISA) 2022, on 4,552 age-15 students from 154 U.S. secondary schools, obtained from <https://www.oecd.org/en/data/datasets/pisa-2022-database.html#data>. Students individually responded to a 45-item questionnaire, indicating how much COVID-19 impacted their access to various teaching and learning pactices and resources (items), by responding to each item on either a 2-, 3-, (for most items) 4-, or 5-point agreement rating scale. Also, each student was continuously scored on two measures of cognitive activation in mathematics, namely, fostering reasoning, and encouraging mathematical thinking.

The [Kendall](#page-7-14) [\(1945\)](#page-7-14) τ_b correlation statistic (which adjusts for tied rankings) was computed for each pair of the 47 variables, resulting in 1,081 two-tailed tests of the null hypothesis that $\tau_b = 0$, after weighting each student to adjust for student oversampling and for each school being sampled with probability proportional to its size (using senate weights which sum to 5,000 over the U.S. students; [Jerrim et al., 2017\)](#page-7-15), and after pairwise deletion of missing responses (number of observations ranged from 745 to 4,392, with median

1,403, over the 1,081 pairwise correlations). The τ_b statistic is the basis for the two-group [Wilcoxon](#page-8-3) [\(1945\)](#page-8-3)-[Mann & Whitney](#page-7-16) [\(1947\)](#page-7-16) rank sum test, and the multi-group [Jonckheere](#page-7-17) [\(1954\)](#page-7-17)[-Terpstra](#page-8-4) [\(1952\)](#page-8-4) median trend test [\(Kendall, 1962,](#page-7-18) §3.12,§13.9).

Figure 1 presents the results of the DP-based MTP sensitivity analysis. This shows that the DP prior with small prior mass $M = 10^{-5}$) leads to supporting a large range of MTPs controlling either the FWER or FDR and valid under arbitrary dependence between the p -values. This leads to prior random threshold functions $\Delta(H_{(r)})$ (over $r \in [0,m]$) that cover the entire lower right triangle below the red line defining the BH MTP threshold, supporting the assertion that this MTP controls FDR under dependence [\(Farcomeni, 2006\)](#page-6-9). Also, for p-values ≤ 0.01 (for the remaining p-values > 0.01 , resp.), the insensitivity measure based on the DP prior predictive [\(5\)](#page-3-0) had median 0.97, MAD 0.04, min 0.44, and max 1.00 (had median 0.00, MAD 0.00, min 0.00, max 0.42, resp.). Naturally, the level of insensitivity increases as the p -value decreases, corresponding to greater confidence of a significant result.

Figure 1: For various MTPs, significance thresholds $\Delta_{\alpha}(H_{(r)})$ over $r \in [0, m]$ (lines), at the $\alpha = 0.05$ level, relative to $m = 1,081$ p-values (hypothesis tests). The weighted Bonferroni MTP thresholds are based on 1,000 samples from the $Dirichlet_m(1, \ldots, 1)$ distribution, respectively. The DP random MTP thresholds are based on 1,000 samples from the Dirichlet $m(M\nu_0(B_1), \ldots, M\nu_0(B_m))$ distribution, with mass parameter $M = 10^{-5}$ and baseline ν_0 matching the probability measure ν defining the BY MTP.

Acknowledgement

This research is supported in part by Spencer Foundation grant SG200100020; National Science Foundation grants SES-0242030 and SES-1156372; and National Institute for Health grants R01HS1018601 and 1R01AA028483-01. The author declares no conflict of interest.

References

- Benjamini, Y. & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society, Series B*, 57, 289–300.
- Benjamini, Y. & Hochberg, Y. (1997). Multiple hypotheses testing with weights. *Scandinavian Journal of Statistics*, 24, 407–418.
- Benjamini, Y., Krieger, A., & Yekutieli, D. (2006). Adaptive linear step-up procedures that control the false discovery rate. *Biometrika*, 93, 491–507.
- Benjamini, Y. & Yekutieli, D. (2001). The control of the false discovery rate in multiple testing under dependency. *Annals of Statistics*, 29, 1165–1188.
- Biswas, A., Chattopadhyay, G., & Chatterjee, A. (2022). Bias-corrected estimators for proportion of true null hypotheses: application of adaptive FDR-controlling in segmented failure data. *Journal of Applied Statistics*, 49, 3591–3613.
- Blanchard, G. & Roquain, E. (2008). Two simple sufficient conditions for FDR control. *Electronic Journal of Statistics*, 2, 963–992.
- Blanchard, G. & Roquain, E. (2009). Adaptive false discovery rate control under independence and dependence. *Journal of Machine Learning Research*, 10, 2837–2871.
- Blanchard, G. & Roquain, E. (2018). Self-consistent multiple testing procedures. *arXiv*, eprint 0802.1406, 1–30.
- Bonferroni, C. (1936). Teoria statistica delle classi e calcolo delle probabilita.` *Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di Firenze*, 8, 3–62.
- Box, G. (1980). Sampling and Bayes' inference in scientific modelling and robustness (with discussion). *Journal of the Royal Statistical Society, Series A*, 143, 383–430.
- Dickhaus, T. (2013). Randomized p-values for multiple testing of composite null hypotheses. *Journal of Statistical Planning and Inference*, 143, 1968–1979.
- Dickhaus, T. (2014). *Simultaneous Statistical Inference*. Berlin Heidelberg: Springer-Verlag.
- Dickhaus, T., Straßburger, K., Schunk, D., Morcillo-Suarez, C., Illig, T., & Navarro, A. (2012). How to analyze many contingency tables simultaneously in genetic association studies. *Statistical Applications in Genetics and Molecular Biology*, 11, Article 12.
- Farcomeni, A. (2006). More powerful control of the false discovery rate under dependence. *Statistical Methods and Applications*, 15, 43–73.
- Ferguson, T. (1973). A Bayesian analysis of some nonparametric problems. *Annals of Statistics*, 1, 209–230.
- Fithian, W. & Lei, L. (2022). Conditional calibration for false discovery rate control under dependence. *Annals of Statistics*, 50, 3091–3118.
- Fraser, D. (2011). Is Bayes posterior just quick and dirty confidence? *Statistical Science*, 26, 299–316.
- Fraser, D. & Reid, N. (2016). Crisis in science? Or crisis in statistics! Mixed messages in statistics with impact on science. *Journal of Statistical Research*, 48, 1–9.
- Gosselin, F. (2011). A new calibrated Bayesian internal goodness-of-fit method: Sampled posterior *p*-values as simple and general p-values that allow double use of the data. *PLOS ONE*, 6, 1–10.
- Greenland, S. (2005). Multiple-bias modelling for analysis of observational data. *Journal of the Royal Statistical Society, Series A*, 168, 267–306.
- Hochberg, Y. & Tamhane, A. (1987). *Multiple Comparison Procedures*. New York: John Wiley and Sons.
- Holm, S. (1979). A simple sequentially rejective multiple test procedure. *Scandinavian Journal of Statistics*, 6, 65–70.
- Javanmard, A. & Montanari, A. (2015). On online control of false discovery rate. *arXiv*, eprint 1502.06197, 1–31.
- Javanmard, A. & Montanari, A. (2018). Online rules for control of false discovery rate and false discovery exceedance. *Annals of Statistics*, 46, 526–554.
- Jerrim, J., Lopez-Agudo, L., Marcenaro-Gutierrez, O., & Shure, N. (2017). To weight or not to weight? The case of PISA data. In *Proceedings of the XXVI Meeting of the Economics of Education Association, Murcia, Spain* (pp. 29–30).
- Jonckheere, A. (1954). A distribution-free k-sample test against ordered alternatives. *Biometrika*, 41, 133– 145.
- Kendall, M. (1945). The treatment of ties in ranking problems. *Biometrika*, 33, 239–251.
- Kendall, M. (1962). *Rank Correlation Methods (3rd Ed.)*. London: Griffin.
- Kim, K. & van de Wiel, M. (2008). Effects of dependence in high-dimensional multiple testing problems. *BMC Bioinformatics*, 9, 1–12.
- Mann, H. & Whitney, D. (1947). On a test of whether one of two random variables is stochastically larger than the other. *Annals of Mathematical Statistics*, 18, 50–60.
- Moran, G., Blei, D., & Ranganath, R. (2024). Holdout predictive checks for Bayesian model criticism. *Journal of the Royal Statistical Society, Series B*, 86, 194–214.
- Murray, M. & Blume, J. (2021). FDRestimation: Flexible False Discovery Rate Computation in R. *F1000Research*, 10, 1–26.
- Neumann, A., Bodnar, T., & Dickhaus, T. (2021). Estimating the proportion of true null hypotheses under dependency: A marginal bootstrap approach. *Journal of Statistical Planning and Inference*, 210, 76–86.
- R Core Team (2024). *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria.
- Rosenbaum, P. (2002). *Observational Studies (2nd Ed.)*. New York: Springer-Verlag.
- Tamhane, A. & Gou, J. (2018). Advances in p-value based multiple test procedures. *Journal of Biopharmaceutical Statistics*, 28, 10–27.
- Tamhane, A. & Gou, J. (2022). Multiple test procedures based on p-values. In *Handbook of Multiple Comparisons* (pp. 11–34). Boca Raton, Florida: CRC Press.
- Terpstra, T. (1952). The asymptotic normality and consistency of Kendall's test against trend, when ties are present in one ranking. *Indagationes Mathematicae*, 14, 327–333.
- U.S. Department of Health and Human Services, Food and Drug Administration (2021). *E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials: Guidance for Industry*. Technical report, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, U.S.A.
- U.S. Department of Health and Human Services, Food and Drug Administration (2022). *Multiple Endpoints in Clinical Trials: Guidance for Industry*. Technical report, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, U.S.A.
- Wasserstein, R. & Lazar, N. (2016). The ASA's statement on p-values: Context, process, and purpose. *American Statistician*, 70, 129–133.

Wilcoxon, F. (1945). Individual comparisons by ranking methods. *Biometrics Bulletin*, 1, 80–83.